<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Popping, S.</style></author><author><style face="normal" font="default" size="100%">Bade, D.</style></author><author><style face="normal" font="default" size="100%">Boucher, C.</style></author><author><style face="normal" font="default" size="100%">van der Valk, M.</style></author><author><style face="normal" font="default" size="100%">El-Sayed, M.</style></author><author><style face="normal" font="default" size="100%">Sigurour, O.</style></author><author><style face="normal" font="default" size="100%">Sypsa, V</style></author><author><style face="normal" font="default" size="100%">Morgan, T.</style></author><author><style face="normal" font="default" size="100%">Gamkrelidze, A.</style></author><author><style face="normal" font="default" size="100%">Mukabatsinda, C.</style></author><author><style face="normal" font="default" size="100%">Deuffic-Burban, S.</style></author><author><style face="normal" font="default" size="100%">Ninburg, M.</style></author><author><style face="normal" font="default" size="100%">Feld, J.</style></author><author><style face="normal" font="default" size="100%">Hellard, M.</style></author><author><style face="normal" font="default" size="100%">Ward, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals</style></title><secondary-title><style face="normal" font="default" size="100%">J Virus Erad</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of virus eradication</style></alt-title><short-title><style face="normal" font="default" size="100%">Journal of virus eradicationJournal of virus eradication</style></short-title></titles><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jan 1</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">5</style></volume><pages><style face="normal" font="default" size="100%">60-66</style></pages><isbn><style face="normal" font="default" size="100%">2055-6640 (Print)2055-6640 (Linking)</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Hepatitis B virus (HBV) and hepatitis C virus (HCV) affect more than 320 million people worldwide, which is more than HIV, tuberculosis (TB) and malaria combined. Elimination of HBV and HCV will, therefore, produce substantial public health and economic benefits and, most importantly, the prevention of 1.2 million deaths per year. In 2016, member states of the World Health Assembly unanimously adopted a resolution declaring that viral hepatitis should be eliminated by 2030. Currently, few countries have elimination programmes in place and even though the tools to achieve elimination are available, the right resources, commitments and allocations are lacking. During the fifth International Viral Hepatitis Elimination Meeting (IVHEM), 7-8 December 2018, Amsterdam, the Netherlands, an expert panel of clinicians, virologists and public health specialists discussed the current status of viral hepatitis elimination programmes across multiple countries, challenges in achieving elimination and the core indicators for monitoring progress, approaches that have failed and successful elimination plans.</style></abstract><accession-num><style face="normal" font="default" size="100%">30800429</style></accession-num><notes><style face="normal" font="default" size="100%">Popping, StephanieBade, DeboraBoucher, Charlesvan der Valk, MarkEl-Sayed, ManalSigurour, OlafssonSypsa, VanaMorgan, TimothyGamkrelidze, AmiranMukabatsinda, ConstanceDeuffic-Burban, SylvieNinburg, MichaelFeld, JordanHellard, MargaretWard, JohnengEditorialEngland2019/02/26 06:00J Virus Erad. 2019 Jan 1;5(1):60-66.</style></notes><custom2><style face="normal" font="default" size="100%">6362901</style></custom2><auth-address><style face="normal" font="default" size="100%">Department of Viroscience, Erasmus Medical Center, Erasmus University, Rotterdam, the Netherlands.Virology Education, Utrecht, the Netherlands.Amsterdam UMC location Meibergdreef, Amsterdam, the Netherlands.Department of Pediatrics, Ain Shams University, Cairo, Egypt.Division of Gastroenterology, Department of Medicine, Landspitali University Hospital, Reykjavik, Iceland.Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Greece.Gastroenterology Section, VA Long Beach Healthcare System, Long Beach, CA, USA.National Center for Disease Control and Public Health, Tbilisi, Georgia.Kigali University, Kigali, Rwanda.Inserm, Universite Paris Diderot, UFR de Medicine-site Bichart, Paris, France.World Hepatitis Alliance, London, UK.Toronto Centre for Liver Disease, Sandra Rotman Centre for Global Health, University of Toronto, Toronto, Canada.Disease Elimination Program, Burnet Institute, Melbourne, Australia.National Center for HIV, Viral Hepatitis, STD, and TB, CDC, Atlanta, GA, USA.Task Force for Global Health, Decatur, Atlanta, GA, USA.</style></auth-address></record></records></xml>